Cortex Pharmaceuticals - AMPAKINE Compounds - Ownership and Business Overview

Life ScienceCompany

Cortex Pharmaceuticals - AMPAKINE Compounds Ownership

Who owns Cortex Pharmaceuticals - AMPAKINE Compounds?

Cortex Pharmaceuticals - AMPAKINE Compounds is owned by Biovail. It was acquired on March 26, 2010.

Cortex Pharmaceuticals - AMPAKINE Compounds Business Overview

Where is Cortex Pharmaceuticals - AMPAKINE Compounds headquartered?

Cortex Pharmaceuticals - AMPAKINE Compounds is headquartered in Irvine, California.

What sector is Cortex Pharmaceuticals - AMPAKINE Compounds in?

Cortex Pharmaceuticals - AMPAKINE Compounds is a life science company.

Life Science M&A Summary in 2010

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2010. The largest life science acquisition in 2010 was Solvay Pharmaceuticals - which was acquired by Abbott Laboratories for $6.1B.

Join Mergr to view all 138 acquisitions of life science companies in 2010, including 15 acquisitions by private equity firms, and 123 by strategics.

Cortex Pharmaceuticals - AMPAKINE Compounds

Irvine, California 92618
United States,

Cortex Pharmaceuticals - AMPAKINE Compounds include the Phase 2 compound CX717, the preclinical compounds CX1763 and CX1942, and the injectable dosage form of CX1739. CX717 modulates AMPA-type glutamate receptors and is in development to prevent respiratory depression in the surgical setting. The incidence of respiratory depression related to opioid administration has been estimated to be up to 17% when oxygen desaturation is used as the indicator.


 Subscribe to unlock this and 201,649
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.